Immunitybio Inc

IBRX

NASDAQ. Currency in USD

5.72 -0.72 ( -11.18% )

Real time prices: December 19

Market Cap.
2.29B
Beta (5Y monthly)
-
Price/Earnings
-
EPS (TTM)
-1.01
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
1.77M
1y Target Est.
9.00
Day's Range
5.71
-
6.47
52 Week's Range
2.60
-
7.85

Historical Summary

Performance
EPS growth
Share Buybacks

About Immunitybio Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://immunitybio.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
397.60M
Employees
760
Address
3530 John Hopkins Court, San Diego, CA, United States, 92121
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.

Latest news

Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday
Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after...
By Benzinga - 19 weeks ago

Why Hill International Is Trading Higher By 15%; Here Are 30 Stocks Moving Premarket
Why Hill International Is Trading Higher By 15%; Here Are 30 Stocks Moving Premarket

Gainers NewAge, Inc. (NASDAQ: NBEV) shares rose 19.7% to $0.2432 in pre-market trading. NewAge recently...
By Benzinga - 22 weeks ago

Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue Estimates
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue Estimates

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 1.14% and 13.35%, respectively, for...
By Zacks Investment Research - 24 weeks ago

Celldex Therapeutics (CLDX) Reports Q2 Loss, Lags Revenue Estimates
Celldex Therapeutics (CLDX) Reports Q2 Loss, Lags Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of -34.88% and 53.43%, respectively, for the quarter...
By Zacks Investment Research - 24 weeks ago

Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue Estimates
Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue Estimates

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -27.27% and 64.68%, respectively, for the...
By Zacks Investment Research - 25 weeks ago

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022

Upgrades Bernstein upgraded the previous rating for Cognex Corp (NASDAQ:CGNX) from Market Perform to Outperform....
By Benzinga - 25 weeks ago